Solvias and Enzymicals join forces in contract research, development and sustainable manufacturing.

Customers of both parties will benefit from proprietary catalyst portfolios and expertise for catalytic transformations with a suite of related custom synthesis and technology platforms. In additional, analytical testing solutions can be offered.

In the past decade both chemocatalysis and bio-catalysis have become strategic assets widely applicable to asymmetric reactions. Smart use of these processes can result in novel synthetic approaches in the area of process development with the common objective of achieving a more sustainable manufacturing.

CEO of Enzymicals AG, Dr. Ulf Menyes, said: “During our successful activities in industrial biocatalysis for diverse markets, we are constantly faced with the outstanding efficiency of chemocatalysis. The incorporation of the transformational power of Solvias ligands in our propositions now enables our customers to investigate a much wider range of solutions from the early beginning. In particular, the combination of both technologies within chemo-enzymatic cascades represents an innovative and currently very promising path for cost-efficient production strategies. I am really pleased that with Solvias we have a strong collaboration partner with complementary technology and expertise.”

Solvias’ Head of Ligands & Specialty Products, Dr. Jürgen Rotzler, said: “Overall, both, chemocatalysis and biocatalysis, are well-established technologies for large-scale production. The huge variety of commercially available ligands and the opportunity to tailor enzymes to specific needs by evolution provides chemists with complementary technologies to tackle everyday challenges in organic chemistry. We are very happy to be now able to add a further component to our scientist’s tool box by collaborating with Enzymicals and therefore to support our customers to a greater extend in bringing better and safer products to the market faster.”

About Solvias AG

Solvias is an established worldwide leader in contract research, development and manufacturing with headquarters in Kaiseraugst near Basel, Switzerland. Our highly qualified employees deliver unrivaled expertise, service and value to customers in the pharmaceutical, biotech, material science and cosmetic industries.

Our laboratories operate to the highest standards and in accordance with ISO, GMP, GLP and FDA regulations. Drawing on a proven 20-year track record of scientific excellence, we provide integrated services to develop, analyze and test a wide range of chemical substances and biopharmaceuticals, enabling our customers to bring safer and better products to the market faster.

Solvias owns the most divers library of ligands for chemocatalysis, produces and commercializes a wide variety of chiral phosphine ligands and catalysts for use in catalytic asymmetric hydrogenation and many other asymmetric catalytic reactions. Several of these ligands / catalysts are used in industrial production processes.

For more information, please visit https://www.solvias.com